Mereo BioPharma Group plc - Asset Resilience Ratio

Latest as of June 2020: 0.00%

Mereo BioPharma Group plc (MAH0) has an Asset Resilience Ratio of 0.00% as of June 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Mereo BioPharma Group plc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

€0.00

≈ $0.00 USD Cash + Short-term Investments

Total Assets

€109.78 Million

≈ $128.35 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2019)

This chart shows how Mereo BioPharma Group plc's Asset Resilience Ratio has changed over time. See Mereo BioPharma Group plc net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Mereo BioPharma Group plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MAH0 company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€0.00	0%
Total Liquid Assets	€0.00	0.00%

Asset Resilience Insights

Limited Liquidity: Mereo BioPharma Group plc maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

Mereo BioPharma Group plc Industry Peers by Asset Resilience Ratio

Compare Mereo BioPharma Group plc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Mereo BioPharma Group plc (2017–2019)

The table below shows the annual Asset Resilience Ratio data for Mereo BioPharma Group plc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2019-12-31	0.00%	€0.00 ≈ $0.00	€86.45 Million ≈ $101.07 Million	--
2018-12-31	3.72%	€2.50 Million ≈ $2.92 Million	€67.28 Million ≈ $78.65 Million	+1.12pp
2017-12-31	2.60%	€2.50 Million ≈ $2.92 Million	€96.34 Million ≈ $112.63 Million	--

pp = percentage points

About Mereo BioPharma Group plc

F:MAH0 Germany Biotechnology

Market Cap

$49.26 Million

€42.14 Million EUR

Market Cap Rank

#23596 Global

#2056 in Germany

Share Price

€0.26

Change (1 day)

+8.20%

52-Week Range

€0.20 - €2.45

All Time High

€4.48